---

$51.49

-0.1800 ( -0.35% ) 224.9K

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-01-09	Sale	-5545.00	LOUMEAU ERIC J
2024-01-09	Sale	-5245.00	MULROY DENNIS
2024-01-09	Sale	-17850.00	Faga Daniel
2024-01-05	Sale	-79780.00	LOUMEAU ERIC J
2024-01-05	Sale	-16510.00	RENTON HOLLINGS
2024-01-05	Sale	-16510.00	Orwin John A
2024-01-05	Sale	-16510.00	Schmid John P.
2024-01-05	Sale	-16510.00	Marquet Magda
2024-01-05	Sale	-115540.00	Lizzul Paul F.
2024-01-05	Sale	-16510.00	Ware J. Anthony